| HLX60 |
Solid Tumors and Lymphoma
|
Phase I
|
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
|
| HLX53 |
Solid Tumors or Lymphoma
|
Phase I
|
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma
|
| HLX10+HLX208 |
NSCLC With BRAF V600E Mutation
|
I b/Phase Ⅱ
|
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
|
| HLX10+HLX26 |
Solid Tumours
|
Phase I
|
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor
|
| HLX10+HLX07 |
Squamous Non-small-cell Lung Cancer
|
Phase III
|
A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) +HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
|
